Maxim Group Reaffirms Their Hold Rating on Gilead Sciences (GILD)
Maxim Group analyst Michael Okunewitch maintained a Hold rating on Gilead Sciences (GILD – Research Report) today. The company’s shares closed ...
StockStory.org on MSN2d
Why Gilead Sciences (GILD) Stock Is Trading Up Today
What Happened? Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' ...
FiercePharma2d
Gilead, riding high from HIV sales boost, charts course for long-acting PrEP launch
With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...
Gilead price target raised to $123 from $113 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $123 from $113 and keeps an Overweight rating on the ...
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...
StockStory.org on MSN4d
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7.4% last ...